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TARGETS FOR KILLER Τ CELLS
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Department of Immunohaematology, University Hospital, Leiden (The Netherlands)
In tumour immunity as in allograft immunity killer Τ cells are thought to
play an essential role in the response . Although more is known of the target
antigens in the latter case, the gene products involved have never been pre-
cisely defined. The main tool for the investigation of these antigens is the
cell mediated lympholysis (CML) assay, in which allogeneic, PHA-induced, blast
cells (T cells) were used as targets . Generalizations deduced from this assay
can thus be applied to situations involving killer Τ cells and other foreign
tissues, only after due consideration of the phenotypic differences existing
between these and PHA-blasts.
It is generally agreed that when a CML test is performed between two random-
ly selected individuals most of the structures recognized are associated with
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gene products in the HLA region . Fmrthermore it is strongly argued that the
HLA-A, -B and -C antigens defined by tissue typing sera and complement are the
antigens involved . These are hereafter referred to as HLA-SD antigens.
Despite these claims the data remains ambiguous in the sense that some foreign
HLA-SD antigens elicit weak or zero killer cell response
In addition to these apparent anomalies we and others ' ' have found
that the association of the target antigen with HLA-SD specificities is often
incomplete in that not all target cells which carry the appropriate antigen in
an unrelated panel are killed and when segregation studies are performed in
families the pattern obtained is untypical of HLA-SD antigens which normally
segregate in a codominant way. Α recessive pattern may, in theory, have account-
ed for this, because in the mouse there existed a recessive H-2 associated
antigen, the haemopoietic resistence (Hh) antigen which segregated in a re-
cessive manner and which was identifiable by CML ' . However, no such pattern
has yet been observed with HLA associated CML antigens in man, neither did it
f i t our data .
Recent new ideas, which had their conceptual origins in certain mouse expe-
riments have led us to reexamine the assumption that HLA-SD antigens are Τ
cell targets. In these mouse experiments foreign minor hιstocompatibi1ity anti-
gens were shown to be capable of eliciting killing reactions only if they were
accompanied on the target cell by H-2D and Κ (HLA-SD equivalent) antigens of
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the ' s e i f type. Such antigens were expressed on the effector and target ce))
and could thus be excluded as the targets in themselves. Nevertheless both
'seif H-2D and/or Κ and the minor 'foreign' antigen was required for killing
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and
<
 neither alone eticited a killing response ' .
Following these observations an opportunity arose in man to study a simllar
phenomenon and the results formed the basis of the classification of antigens
proposed here.
Initially a patient (Mrs. R e e f . ) , who had been suffering from aplastic
anaemia, was studied. She had received multiple blood transfusions and a bone
marrow allograft from her HLA identical brother which was ultimately rejected.
Thereafter her periphera] blood lymphocytes were shown to be capable of killing
target cells from her HLA identical brother thus suggesting that minor histo-
compatibi1ity antigens were recognized. It was subsequently shown that when
these effector cells were tested on a panel of targets from unrelated indivi-
duals only male HLA-A2 positive, targets were killed despite the fact that the
HLA-A2 antigen was a 'seif antigen present on the cells of Mrs. Reef. herseif.
This led to the conclusion that the target was a minor histocompatibi1ity anti-
gen (H-Y) encoded on the Υ sex chromosome and that killing required the simul-
taneous expression of the 'seif compatible HLA-A2 antigen on effector and
target. Hitherto three examples of this phenomenon have been described and in
all cases an HLA-A2 restricted H-Y killing occurred, but in one case this was
supplernented by restriction to another 'seif compatible antigen, the HLA-B7
antigen .
The methods used for the cell mediated lympholysis (CML) technique have beer
described in detail el sewhere 2''. Brief ly periphera) blood lymphocytes were sen-
sitized in vitro in one-way MLC's where responder cells, A, were sensitized to
irradiated cells B. After 6 days these cells were tested in a k hour killing
assay on PHA blast cells obtained at 3 days of culture. These had been pre-
viously labelled with sodium chromate so that the degree of killing could be
measured by the amount of isotope released into the supernatant. Controls in-
cluded PHA blasts of the original sensitizing cell, B, as positive control and
autologous, A, PHA blasts as negative control. Since one of the two major
sources of Variation in these studies was the ability of PHA blasts to take up
and release Cr the results were always corrected for the difference between
spontaneous release and maximal release for each individual target cell used.
The second major source of Variation was the size of the effector cell clone
which in turn determined the maximum kill by any effector cell population. In
the data shown positive reactions were those which gave percentage kill values
comparable to the positive control value (see for further discussion refs.
18,28,
In two series of experiments an association between antigens recognized in
CML and 'seif HLA-SD was demonstrated. In both cases the latter were excluded
as the antigens in themsetves because the same antigens were present on the
effector cel1s.
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Fig. 1. Schematic representation of a target cel1 showing two types of targets
for Τ ki 1 ler cells. The foreign component of the complex target rnay be encoded
outside the major histocompatibi1ity complex (HAM-minor) or in linkage with it
(HAM-major). These two examples are further described in the text.
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Fig. 2. Summary of results obtained from a panel of 70 individuals who had
been typed with various antisera which recognized the Bw35 group of antigens,
and with two CML effector cell preparations (m and n) which recognized Bw3S
associated antigens, a and b.
In an attempt to clarify what at first appeared to be confusing observations,
a hypothetical classification of antigens ij now proposed. In genera) it could
be said that two types of antigen exist bcih being associated with 'seif' HLA-SD
antigens at the cell membrane level. Under no circumbLances is the association
referred to meant to imply molecular interaction between the HLA-SD determinant
and the other determinant concerned, this question remains open. The term is
used solely to imply that a simultaneous (associated) recognition of both anti-
gens must occur before killing takas place. Antigens which are HLA Associated
at the Membrane are abbreviated to HAM antigens. These can be subdivided into
antigens which are encoded outside the HLA region, as in the case of minor his-
tocompatibί1ity antigens from which we derive the term HAM minor antigens, or,
alternatively they can be in linkage with the HLA complex and are thus products
of the major histocompatibi1ity complex and because of this we derive the term
HAM major antigens (see F i g . 1 ) .
An example of a HAM minor antigen was one which was encoded on the Υ chromo-
some. It was recognized in association with the 'seif compatible HLA-A2 anti-
gen and it ocurred in three independent cases, one of which also involved HLA-
B7. These results were described elsewhere
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Α possible example of a HAM major antigen was an antigen which was recogniz-
ed by effector cells raised in vitro between HLA-SD identical, but genotypical-
ly HLA non-identical, family members. These data have been mostly described
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elsewhere . Family segregation studies were compatible with the view that the
antigens detected by CML (a and b) were encoded in the HLA region. When tested
upon an extensive panel of individuals who typed positively or negatively for
HLA-Bw35 and/or its W4 associated antigen, Bw53, only individuals who carried
these HLA-SD antigens were killed. Fifty-five individuals who carried Bw35 and/
or Bw53 were tested and it was remarkable that cells from all 55 individuals
were killed by either anti-a or anti-b. None of the 17 individuals who were
negative for these HLA-SD antigens were positive and although this rendered the
possibility of non Bw35/53's being killed highly unlikely, further confirmation
of this awaited the testing of a larger panel (Fig. 2 ) . The reaction pattern
obtained with the effector cells, anti-a and anti-b, failed to correlate with
any of the patterns obtained with the available typing sera. These CML defined
antigens therefore appeared to fulfill the criteria for HAM major antigens in
that they were encoded in the major histocompatibi1ity complex and were seen
only in association with specific 'seif compatible HLA-SD antigens.
One Interpretation of this data is that HAM major antigens foilow the same
rules of associative recognition as have already been demonstrated for HAM mino
antigens and that a similar complex antigen is formed by the products of two
separate cistrons which are in this case both encoded in the HLA region. In
suggesting this it should be stated that we cannot completely exclude the pos-
sibility that these CML specificities are in fact represented within ehe HLA-SD
typing sera used, most of which are clearly multivalent (Fig. 2 ) . An alternativ
Interpretation is that Τ killer cells recognize a carrier molecuie plus an
appropriate hapten (Bw35/53) whereas the antisera only recognize the hapten
portion of the molecuie.
The view that HLA-SD antigens in themselves acted as target antigens in CML
t was lent further support by some recent experiments in man 2- 5. In general, how-
ever the data remain inconclusive, it was first suggested that such antigens
were associated with killing when it was shown in the mouse that target cells
which had been previously ineubated with anti-H-2 sera subsequentiy became re-
sistent to killing . Furthermore mouse cell 1ines which failed to express the
molecules carrying H-2D and Κ antigens were neither capable of sensitizing nor
capable of being killed in CML assays, thus implying a specific role for these
molecular struetures in Τ cell killing, despite the possibility that they may
31 32
not be targets in themselves .
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In man discrepancies have been recorded regarding the behaviour of HLA-SD
antigens as targets in so far that not all antigens performed equally well in
the generation of effector cells. It was suggested that the antigens HLA-A2,
-B7> -B8, -B12, -Bw35 were strong immunogens whereas others were weak immuno-
gens e.g. HLA-A1, -A3, -B11, and -Aw19 . Such observations were originally
interpreted to Support a Suggestion that target antigens constituted an inte-
gral part of the 'backbone' structure of the HLA-SD molecules which were Seen
exclusively by killer Τ cells 1 6' 1 8.
HLA-D region products have hitherto been considered by most workers to be
incapable of behaving as targets for Τ killer cells *ϋ>5 _ However most
attempts to demonstrate HLA-D target antigens have used 'conventional' CML
assays of the type described here. Three pieces of data suggested that this may
have been an inappropriate technique. Firstly, in the mouse it was possible to
demonstrate CML to all regions of the H-2 complex, including the H-2 IA region
(HLA-D equivalent), providing the appropriate technical modifications were in-
35"37
troduced . Secondly, gene products of the Mls locus in the mouse, which
induced strong proliferative responses in allogeneic cel1 mixtures consistently
failed to behave as targets in conventional CML assays but were thought to be
detectable by the so called 'cytostasis' assay in which macrophage monolayers
-50
were used as targets . Thirdly, it was recently demonstrated in man that in
CML assays in which blood monocyte-macrophage cells were used as target cells,
39
HLA-DR associated gene products could behave as antigens
Finally, with regard to the relevance of this discussion to tumour immunity
one should mention phenomena in mouse tumour modeis where, in sonne cases,
40 ^1
changes in the H-2D and Κ structures have been observed ' . In others H-2D
and Κ restricted CML reactions to tumour associated antigens have been demon-
strable ' . However, exceptions to this latter phenomenon have also been des-
cribed . We feel therefore that it is legitimate to suggest that tumour asso-
ciated antigens in man may in some cases form antigen complexes in association
with 'seif HLA-SD antigens which are recognized by the host's killer Τ cells.
SUMMARY
"Conventional" CML assays in man have been widely used to investigate anti-
gens recognized by killer Τ cells. Although the detection of these antigens
appears to be dependent on expression of the molecular structures which carry
HLA-SD (HLA-A, -B and -C encoded serologically defined) antigens there is no
clear evidence that these behave as targets in themselves. Two hypothetical
categories of targets detected by killer Τ cells are proposed both of which
are HLA-SD Associated at the cell Membrane level (HAM). The allogeneic or
foreign portion of the HAM antigen may be encoded outside the major histocompa-
tibility complex and such a complex is termed a HAM minor antigen, and an
example is given of the HLA-A2 associated H-Y antigen. AIternatively it may be
encoded in 1inkage with the major histocompatibi1ity complex and is thus termed
a HAM major antigen. Α possible example of this is an HLA encoded antigen which
is associated with the HLA-Bw35 group of antigens. If such a classification is
generally applicable, it may explain some of the apparent ambiguities regarding
HLA-SD antigens and targets for ki1ler Τ cells.
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In man discrepancies have been recorded regarding the behaviour of HLA-SD
antigens as targets in so far that not all antigens performed equally well in
the generation of effector cells. It was suggested that the antigens HLA-A2,
-B7, -68, -B12, -Bw35 were strong imniunogens whereas others were weak immuno-
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gens e.g. HLA-Al, -A3, -B11, and -Awl9 . Such observations were original ly
interpreted to support a Suggestion that target antigens constituted an inte-
gral part of the 'backbone' structure of the HLA-SD molecules which were seen
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exclusively by killer Τ cells ' .
HLA-D region products have hitherto been considered by most workers to be
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incapable of behaving as targets for Τ killer cells ' . However most
attempts to demonstrate HLA-D target antigens have used 'conventional' CML
assays of the type described here. Three pieces of data suggested that this may
have been an inappropriate technique. Firstly, in the mouse it was possible to
demonstrate CML to all regions of the H-2 complex, including the H-2 ΓΑ region
(HLA-D equivalent), providing the appropriate technical modifications were in-
troduced . Secondly, gene products of the Mls locus in the mouse, which
induced strong proliferative responses in allogeneic cel1 mixtures consistently
failed to behave as targets in conventional CML assays but were thought to be
detectable by the so called 'cytostasis' assay in which macrophage monolayers
were used as targets . Thirdly, it was recently demonstrated in man that in
CML assays in which blood monocyte-macrophage cells were used as target cells,
39HLA-DR associated gene products could behave as antigens .
Finally, with regard to the relevance of this discussion to tumour immunity
one should mention phenomena in mouse tumour modeis wnere, in some cases,
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changes in the H-2D and Κ structures have been observed ' . In others H-2D
and Κ restricted CML reactions to tumour associated antigens have been demon-
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strable ' . However, exceptions to this latter phenomenon have also been des-
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cribed . We feel therefore that it is legitimate to suggest that tumour asso-
ciated antigens in man may in some cases form antigen complexes in association
with 'seif HLA-SD antigens which are recognized by the host's killer Τ cells.
SUMMARY
"Conventional" CML assays in man have been widely used to investigate anti-
gens recognized by killer Τ cells. Although the detection of these antigens
appears to be dependent on expression of the molecular structures which carry
HLA-SD (HLA-A, -B and -C encoded serological ly defined) antigens there is no
clear evidence that these behave as targets in themselves. Two hypothetical
categories of targets detected by killer Τ cells are proposed both of which
are HLA-SD Associated at the cel1 Membrane level (HAM). The allogeneic or
foreign portion of the HAM antigen may be encoded outside the major histocompa-
tibility complex and such a complex is termed a HAM minor antigen, and an
example is given of the HLA-A2 associated H-Y antigen. A]ternatively it may be
encoded in linkage with the major histocompatibi1ity complex and is thus termec
a HAM major antigen. Α possibie example of this is an HLA encoded antigen whier
is associated with the HLA-Bw35 group of antigens. If such a classification is
generally applicable, it may explain some of the apparent ambiguities regardinc
HLA-SD antigens and targets for killer Τ cells.
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